Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | FSHR | P23945 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25857102 | 0.99 | ALDH1A1 (0.41) | ALDH1A1P2RX7CTSLCTSBCTSS | |
| SCHEMBL21967065 | 0.83 | MEN1 (0.34) | P2RX7LMNAMEN1KMT2A | |
| SCHEMBL21967075 | 0.82 | KMT2A (0.34) | P2RX7LMNAMEN1KMT2A | |
| SCHEMBL2726118 | 0.81 | STK17B (0.48) | P2RX7MAPKAPK2MEN1KMT2A | |
| SCHEMBL15249204 | 0.80 | CTSS (0.36) | ALDH1A1P2RX7CTSLCTSBCTSS | |
| SCHEMBL2724465 | 0.80 | STK17B (0.47) | P2RX7MAPKAPK2MEN1KMT2A | |
| SCHEMBL25857100 | 0.79 | CTSS (0.38) | ALDH1A1P2RX7CTSLCTSBCTSS | |
| SCHEMBL1284434 | 0.78 | SIRT5 (0.50) | P2RX7LMNASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL16057286 | 0.78 | HTT (0.50) | LMNASMN1; SMN2HTTL3MBTL1KEAP1 | |
| SCHEMBL5149463 | 0.77 | TGM2 (0.50) | LMNASMN1; SMN2HTTL3MBTL1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20180221378-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180201619-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201618-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201617-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-8822683-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | ALDH1A1 1183/4885P2RX7 3653/4885CTSL 2899/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | ALDH1A1 1438/4885P2RX7 4661/4885CTSL 1154/4885 |
| US-20180201618-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | ALDH1A1 1726/4885P2RX7 4351/4885CTSL 1815/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-20180201619-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | ALDH1A1 4055/4885P2RX7 3874/4885CTSL 3197/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | ALDH1A1 1183/4885P2RX7 3653/4885CTSL 2899/4885 |
| US-20180221378-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | ALDH1A1 1726/4885P2RX7 4351/4885CTSL 1815/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | ALDH1A1 1726/4885P2RX7 4351/4885CTSL 1815/4885 |
| US-20180201617-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | ALDH1A1 2981/4885P2RX7 4577/4885CTSL 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.